ARTICLE | Clinical News
Tysabri natalizumab regulatory update
July 26, 2010 7:00 AM UTC
Biogen Idec updated the U.S. label for autoimmune drug Tysabri natalizumab to warn that the risk of progressive multifocal leukoencephalopathy (PML) increases in patients with prior immunosuppressant ...